<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CRD</journal-id>
<journal-id journal-id-type="hwp">spcrd</journal-id>
<journal-id journal-id-type="nlm-ta">Chron Respir Dis</journal-id>
<journal-title>Chronic Respiratory Disease</journal-title>
<issn pub-type="ppub">1479-9723</issn>
<issn pub-type="epub">1479-9731</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1479972313493098</article-id>
<article-id pub-id-type="publisher-id">10.1177_1479972313493098</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Depression in patients with idiopathic pulmonary fibrosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Akhtar</surname>
<given-names>Akhtar A.</given-names>
</name>
<xref ref-type="aff" rid="aff1-1479972313493098">1</xref>
<xref ref-type="corresp" rid="corresp1-1479972313493098"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ali</surname>
<given-names>Mohammad A.</given-names>
</name>
<xref ref-type="aff" rid="aff2-1479972313493098">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Smith</surname>
<given-names>Robin P.</given-names>
</name>
<xref ref-type="aff" rid="aff1-1479972313493098">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1479972313493098">
<label>1</label>Department of Respiratory Medicine, Ninewells Hospital, Dundee, Scotland</aff>
<aff id="aff2-1479972313493098">
<label>2</label>Medical Sciences Division, University of Oxford, John Radcliffe Hospital, Oxford, UK</aff>
<author-notes>
<corresp id="corresp1-1479972313493098">Akhtar A. Akhtar, Department of Respiratory Medicine, Ninewells Hospital, Dundee, DD1 9SY, Scotland. Email: <email>akhtar.akhtar@nhs.net</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>10</volume>
<issue>3</issue>
<fpage>127</fpage>
<lpage>133</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Depression carries enormous global morbidity and is 1.5–7 times likelier to occur in individuals with chronic illness than in the general population. Idiopathic pulmonary fibrosis (IPF) has a rising incidence with a severe impact on quality of life. An indication of the prevalence of depression in this group is therefore of paramount interest. A prospective study was performed. A total of 118 participants with IPF who attended the interstitial lung disease clinic in Ninewells Hospitals, Dundee, Scotland, from May 2010 to September 2011 were recruited. Informed consent was obtained. The male to female ratio was 60:58. The Wakefield Self-assessment of Depression Inventory was used (scores ≥15 denote a depressed state). Pulmonary function tests were measured to correlate disease severity with depression scores. Of them, 58 patients had significant depressive symptoms scoring ≥15; only nine were taking antidepressant medication. The mean depression score of female participants was 15.0 ± 0.77 (SD 5.9), compared with a mean male score of 13.1 ± 0.99 (SD 7.5). Disease severity, age, duration since diagnosis and number of co-morbidities were not significantly correlated with depression. The study population had a high prevalence of depressive symptoms. Medical therapy for pulmonary fibrosis is limited and therefore palliation of symptoms and pulmonary rehabilitation form the main strategy for management. Depression should be actively screened in patients with IPF.</p>
</abstract>
<kwd-group>
<kwd>Pulmonary fibrosis</kwd>
<kwd>depression</kwd>
<kwd>interstitial lung disease</kwd>
<kwd>rehabilitation</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1479972313493098">
<title>Introduction</title>
<p>Idiopathic pulmonary fibrosis (IPF) is a diffuse parenchymal lung disease characterised by a devastating distortion of pulmonary structure by abnormally proliferating fibroblasts.<sup>
<xref ref-type="bibr" rid="bibr1-1479972313493098">1</xref>
</sup> The median duration of symptoms before diagnosis is 1–2 years with most patients referred to cardiology for exertional dyspnoea prior to a respiratory referral.<sup>
<xref ref-type="bibr" rid="bibr2-1479972313493098">2</xref>
</sup> A small minority are asymptomatic at diagnosis; in the remainder, symptoms typically develop 2.7 years after radiographic detection of pulmonary abnormality.<sup>
<xref ref-type="bibr" rid="bibr2-1479972313493098">2</xref>
</sup>
</p>
<p>Several causes for IPF have been proposed, including metal particles, smoking, sawdust and diabetes mellitus.<sup>
<xref ref-type="bibr" rid="bibr1-1479972313493098">1</xref>,<xref ref-type="bibr" rid="bibr3-1479972313493098">3</xref>,<xref ref-type="bibr" rid="bibr4-1479972313493098">4</xref>
</sup> Reflux of gastric contents in gastro-oesophageal reflux disease (GORD) has also long been associated with IPF,<sup>
<xref ref-type="bibr" rid="bibr5-1479972313493098">5</xref>
</sup> and more recent studies have promisingly corroborated this link.<sup>
<xref ref-type="bibr" rid="bibr6-1479972313493098">6</xref>,<xref ref-type="bibr" rid="bibr7-1479972313493098">7</xref>
</sup> Tobin et al. reported 17 IPF patients with 16 having abnormal oesophageal acid exposure<sup>
<xref ref-type="bibr" rid="bibr8-1479972313493098">8</xref>
</sup> and indeed, there are at least four reported cases in the literature, where treatment of GORD in patients with IPF showed improvement in pulmonary function.<sup>
<xref ref-type="bibr" rid="bibr9-1479972313493098">9</xref>
</sup> There is therefore indication of the role of GORD in the pathogenesis and prognosis of IPF.</p>
<p>The association of IPF with multiple co-morbidities, including pulmonary hypertension and emphysema, is well documented.<sup>
<xref ref-type="bibr" rid="bibr8-1479972313493098">8</xref>,<xref ref-type="bibr" rid="bibr10-1479972313493098">10</xref>
<xref ref-type="bibr" rid="bibr11-1479972313493098"/>–<xref ref-type="bibr" rid="bibr12-1479972313493098">12</xref>
</sup> It is also well established that major depressive illness is an extremely burdensome global morbidity.<sup>
<xref ref-type="bibr" rid="bibr13-1479972313493098">13</xref>
<xref ref-type="bibr" rid="bibr14-1479972313493098"/>
<xref ref-type="bibr" rid="bibr15-1479972313493098"/>
<xref ref-type="bibr" rid="bibr16-1479972313493098"/>
<xref ref-type="bibr" rid="bibr17-1479972313493098"/>–<xref ref-type="bibr" rid="bibr18-1479972313493098">18</xref>
</sup> Depression in individuals with chronic illness is 1.5–7 times likelier to occur than in the general population.<sup>
<xref ref-type="bibr" rid="bibr19-1479972313493098">19</xref>
<xref ref-type="bibr" rid="bibr20-1479972313493098"/>–<xref ref-type="bibr" rid="bibr21-1479972313493098">21</xref>
</sup> There is some evidence of the increased incidence of depressive symptoms in IPF patients in studies investigating the quality of life (QoL) status of these patients.<sup>
<xref ref-type="bibr" rid="bibr22-1479972313493098">22</xref>,<xref ref-type="bibr" rid="bibr23-1479972313493098">23</xref>
</sup> However, there remains a prominent paucity of large prospective studies addressing the diagnosis and management of depression in patients with IPF and its impact on the health status of these individuals. With the incidence of IPF at 7.4/100,000 person years, a figure which is seeing an annual increase,<sup>
<xref ref-type="bibr" rid="bibr24-1479972313493098">24</xref>
</sup> an indication of the prevalence of depression in this group is of paramount interest.</p>
<p>Pulmonary rehabilitation remains the main strategy for this group of patients. It has an established role in the management of chronic obstructive pulmonary disease (COPD) and has been previously shown to reduce symptoms of anxiety and depression in these patients.<sup>
<xref ref-type="bibr" rid="bibr25-1479972313493098">25</xref>
</sup> It is also associated with reduced breathlessness, improved health-related QoL and fewer hospital admission.<sup>
<xref ref-type="bibr" rid="bibr26-1479972313493098">26</xref>
</sup>
</p>
<p>The aim of this study was to assess the presence of depressive symptoms in patients suffering from IPF and to investigate whether functional severity of disease correlated with the depression score. Current treatment strategies are also discussed.</p>
</sec>
<sec id="section2-1479972313493098" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section3-1479972313493098">
<title>Participants</title>
<p>A total of 118 patients suffering from IPF who attended the interstitial lung disease clinic at Ninewells Hospital, Dundee, Scotland, from May 2010 to September 2011 were recruited for this study. The diagnosis of pulmonary fibrosis was based on high-resolution computerised tomography of the chest and surgical and transbronchial biopsies of the lung. Patients were excluded if they refused consent, had a lack of competency in completing the questionnaire, had depression prior to a diagnosis of pulmonary fibrosis or whose notes could not be found.</p>
<p>All participants gave informed consent and ethical approval was obtained from the local ethics committee. References for the study are 12/ES/0014 (NHS Tayside Research Ethics Committee reference).</p>
</sec>
<sec id="section4-1479972313493098">
<title>Outcome measures</title>
<p>The Wakefield Self-assessment of Depression Inventory (WDI; <xref ref-type="table" rid="table1-1479972313493098">Table 1</xref>) was used to assess depression status.<sup>
<xref ref-type="bibr" rid="bibr27-1479972313493098">27</xref>
</sup> This consists of 12 questions with 4 possible answers each; participants are asked to read each question carefully, one at a time, and underline or circle the response that best indicates how they feel at the time of completion. Each answer is scored on a scale of 0–3; collating each answer generates a depression rating score of 36. A score of ≥15 suggests a high frequency and intensity of the symptoms often associated with depression (e.g. lethargy, anorexia, low self-esteem, anxiety, etc.), though it does not imply a diagnosis of the condition, similar to alternative depression rating scales.<sup>
<xref ref-type="bibr" rid="bibr28-1479972313493098">28</xref>
</sup> The WDI has previously been used with success in studies investigating depression in patients with other pathologies<sup>
<xref ref-type="bibr" rid="bibr29-1479972313493098">29</xref>,<xref ref-type="bibr" rid="bibr30-1479972313493098">30</xref>
</sup> and, furthermore, can independently be completed by the patient, reducing investigator bias.</p>
<table-wrap id="table1-1479972313493098" position="float">
<label>Table 1.</label>
<caption>
<p>The Wakefield Self-assessment of Depression Inventory.<sup>
<xref ref-type="bibr" rid="bibr25-1479972313493098">25</xref>
</sup>
</p>
</caption>
<graphic alternate-form-of="table1-1479972313493098" xlink:href="10.1177_1479972313493098-table1.tif"/>
<table>
<tbody>
<tr>
<td>A. I feel miserable and sad</td>
<td>B. I find it easy to do the things I used to do</td>
<td>C. I get very frightened or panicky for apparently no reason at all</td>
<td>D. I have weeping spells, or feel like it</td>
</tr>
<tr>
<td>0: <italic>No, not at all</italic>
</td>
<td>0: <italic>Yes, definitely</italic>
</td>
<td>0: <italic>No, not at all</italic>
</td>
<td>0: <italic>No, not at all</italic>
</td>
</tr>
<tr>
<td>1: <italic>No, not much</italic>
</td>
<td>1: <italic>Yes, sometimes</italic>
</td>
<td>1: <italic>No, not much</italic>
</td>
<td>1: <italic>No, not much</italic>
</td>
</tr>
<tr>
<td>2: <italic>Yes, sometimes</italic>
</td>
<td>2: <italic>No, not much</italic>
</td>
<td>2: <italic>Yes, sometimes</italic>
</td>
<td>2: <italic>Yes, sometimes</italic>
</td>
</tr>
<tr>
<td>3: <italic>Yes, definitely</italic>
</td>
<td>3: <italic>No, not at all</italic>
</td>
<td>3: <italic>Yes, definitely</italic>
</td>
<td>3: <italic>Yes, definitely</italic>
</td>
</tr>
<tr>
<td>E. I still enjoy the things I used to</td>
<td>F. I am restless and can’t keep still</td>
<td>G. I get off to sleep easily without sleeping tablets</td>
<td>H. I feel anxious when I go out of the house on my own</td>
</tr>
<tr>
<td>0: <italic>Yes, definitely</italic>
</td>
<td>0: <italic>No, not at all</italic>
</td>
<td>0: <italic>Yes, definitely</italic>
</td>
<td>0: <italic>No, not at all</italic>
</td>
</tr>
<tr>
<td>1: <italic>Yes, sometimes</italic>
</td>
<td>1: <italic>No, not much</italic>
</td>
<td>1: <italic>Yes, sometimes</italic>
</td>
<td>1: <italic>No, not much</italic>
</td>
</tr>
<tr>
<td>2: <italic>No, not much</italic>
</td>
<td>2: <italic>Yes, sometimes</italic>
</td>
<td>2: <italic>No, not much</italic>
</td>
<td>2: <italic>Yes, sometimes</italic>
</td>
</tr>
<tr>
<td>3: <italic>No, not at all</italic>
</td>
<td>3: <italic>Yes, definitely</italic>
</td>
<td>3: <italic>No, not at all</italic>
</td>
<td>3: <italic>Yes, definitely</italic>
</td>
</tr>
<tr>
<td>I. I have lost interest in things</td>
<td>J. I get tired for no reason</td>
<td>K. I am more irritable than usual</td>
<td>L. I wake early and then sleep badly for the rest of the night</td>
</tr>
<tr>
<td>0: <italic>No, not at all</italic>
</td>
<td>0: <italic>No, not at all</italic>
</td>
<td>0: <italic>No, not at all</italic>
</td>
<td>0: <italic>No, not at all</italic>
</td>
</tr>
<tr>
<td>1: <italic>No, not much</italic>
</td>
<td>1: <italic>No, not much</italic>
</td>
<td>1: <italic>No, not much</italic>
</td>
<td>1: <italic>No, not much</italic>
</td>
</tr>
<tr>
<td>2: <italic>Yes, sometimes</italic>
</td>
<td>2: <italic>Yes, sometimes</italic>
</td>
<td>2: <italic>Yes, sometimes</italic>
</td>
<td>2: <italic>Yes, sometimes</italic>
</td>
</tr>
<tr>
<td>3: <italic>Yes, definitely</italic>
</td>
<td>3: <italic>Yes, definitely</italic>
</td>
<td>3: <italic>Yes, definitely</italic>
</td>
<td>3: <italic>Yes, definitely</italic>
</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section5-1479972313493098">
<title>Procedures</title>
<p>Patients were asked to read carefully the instructions on the questionnaire and to complete it as accurately and honestly as possible. The questionnaires were administered by the primary author. Participants were instructed to indicate how they felt at the time of completion, rather than how they were in the past, or how they would hope to be. After completion, questionnaires were handed to a receptionist in an unmarked envelope. Throughout the study, confidentiality was maintained. Functional severity of disease was assessed by various measurements including forced expiratory volume in 1second (FEV<sub>1</sub>), the forced vital capacity (FVC), the ratio of FEV<sub>1</sub> to FVC, the gas transfer factor and the gas constant. Ethical approval was obtained.</p>
</sec>
<sec id="section6-1479972313493098">
<title>Data analysis</title>
<p>The prevalence of depression was calculated by assessing the percentage of participants scoring ≥15 on the WDI. The relationship between depression scores and lung function measurements was investigated by the Pearson’s product-moment correlation coefficient. An unpaired <italic>t</italic> test was used to assess significance between male and female mean depression scores. Basic analyses were conducted using the software Microsoft Excel 2007. The level of significance was set at 0.05.</p>
</sec>
</sec>
<sec id="section7-1479972313493098">
<title>Results</title>
<sec id="section8-1479972313493098">
<title>Demographic summary</title>
<p>The study population comprised of 118 patients (60 males and 58 females). Baseline characteristics are summarised in <xref ref-type="table" rid="table2-1479972313493098">Table 2</xref>. Age ranged between 34 and 96 (68.1 ± 11.35) years. The duration since diagnosis varied from 1 month to 30 years (3.9 ± 4.1 years). Over half of the patients were either current (15) or ex-smokers (59).</p>
<table-wrap id="table2-1479972313493098" position="float">
<label>Table 2.</label>
<caption>
<p>Demographic summary of study population.</p>
</caption>
<graphic alternate-form-of="table2-1479972313493098" xlink:href="10.1177_1479972313493098-table2.tif"/>
<table>
<thead>
<tr>
<th>Characteristic</th>
<th>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male/female</td>
<td align="center">60/58</td>
</tr>
<tr>
<td>Mean age (years)</td>
<td align="center">68.1 ± 11.35<sup>a</sup>
</td>
</tr>
<tr>
<td>Age range (years)</td>
<td align="center">34–96</td>
</tr>
<tr>
<td>Mean duration of symptoms (years)</td>
<td align="center">3.9 ± 4.1<sup>a</sup>
</td>
</tr>
<tr>
<td>Range of duration</td>
<td align="center">1 month–30 years</td>
</tr>
<tr>
<td>Current/ex-smoker</td>
<td align="center">15/59</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>Co-morbidities</th>
<th align="center">
<italic>n</italic> (%) patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Connective tissue disease</td>
<td>23 (19.5)</td>
</tr>
<tr>
<td>COPD</td>
<td>19 (16.1)</td>
</tr>
<tr>
<td>GORD</td>
<td>16 (13.6)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>14 (11.7)</td>
</tr>
<tr>
<td>Obesity</td>
<td>12 (10.2)</td>
</tr>
<tr>
<td>Depression</td>
<td>9 (7.6)</td>
</tr>
<tr>
<td>Sarcoidosis</td>
<td>7 (5.9)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1479972313493098">
<p>COPD: chronic obstructive pulmonary disease; GORD: gastro-oesophageal reflux disease.</p>
</fn>
<fn id="table-fn2-1479972313493098">
<p>
<sup>a</sup>Represented as mean ± SD.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Of them, 16 patients (13.6%) had GORD and 27 (22.9%) were using proton pump inhibitors due to complaints of indigestion. There was significant co-morbidity in the study population, with 92.4% of participants having at least one co-morbidity (<xref ref-type="fig" rid="fig1-1479972313493098">Figure 1</xref>); the commonest co-morbidities were connective tissue disease (23), COPD (19), GORD (16), diabetes (14), obesity (12), depression (9) and sarcoidosis (7).</p>
<fig id="fig1-1479972313493098" position="float">
<label>Figure 1.</label>
<caption>
<p>Frequency of co-morbidities.</p>
</caption>
<graphic xlink:href="10.1177_1479972313493098-fig1.tif"/>
</fig>
</sec>
<sec id="section9-1479972313493098">
<title>Prevalence of depression</title>
<p>A high prevalence of depressive symptoms was found in the sample. The mean depression score was 14.1 ± 0.63 (SD 6.8). A total of 58 patients (49.2%) scored ≥15. Depression scores were subsequently correlated with various parameters including age, duration since diagnosis, number of co-morbidities and lung function measurements (<xref ref-type="table" rid="table3-1479972313493098">Table 3</xref>). Correlation coefficients between depression score and FEV<sub>1</sub> (<italic>r =</italic> −0.20), FVC (<italic>r =</italic> −0.20), gas transfer factor (<italic>r =</italic> −0.23) and the gas constant (<italic>r =</italic> −0.05) were significant (all <italic>p</italic> &lt; 0.05). Correlation between depression score and duration since diagnosis (<italic>r </italic>= −0.11), FEV<sub>1</sub>–FVC ratio (<italic>r </italic>= 0.05), age (<italic>r </italic>= −0.08) and number of co-morbidities (<italic>r </italic>= −0.08) was not significant (all <italic>p</italic> &gt; 0.05).</p>
<table-wrap id="table3-1479972313493098" position="float">
<label>Table 3.</label>
<caption>
<p>Correlation coefficients between depression score and various parameters.</p>
</caption>
<graphic alternate-form-of="table3-1479972313493098" xlink:href="10.1177_1479972313493098-table3.tif"/>
<table>
<thead>
<tr>
<th>Variable</th>
<th>
<italic>r</italic> value</th>
<th>
<italic>p</italic> value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV<sub>1</sub>
</td>
<td>−0.20</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>FVC</td>
<td>−0.20</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Gas transfer factor</td>
<td>−0.23</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Gas constant</td>
<td>−0.05</td>
<td align="center">NS</td>
</tr>
<tr>
<td>FEV<sub>1</sub>–FVC</td>
<td>0.05</td>
<td align="center">NS</td>
</tr>
<tr>
<td>Age</td>
<td>−0.08</td>
<td align="center">NS</td>
</tr>
<tr>
<td>No of co-morbidities</td>
<td>−0.13</td>
<td align="center">NS</td>
</tr>
<tr>
<td>Duration of diagnosis</td>
<td>−0.11</td>
<td align="center">NS</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1479972313493098">
<p>FEV<sub>1</sub>: forced expiratory volume in 1second; FVC: forced vital capacity.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The mean depression score of female participants was 15.0 ± 0.77 (SD 5.9), compared with a mean male score of 13.2 ± 0.99 (SD 7.6; <xref ref-type="fig" rid="fig2-1479972313493098">Figure 2</xref>). This difference was not statistically significant (<italic>t</italic> = −1.39, <italic>p</italic> = 0.17). Of the 58 patients scoring ≥15, only the nine patients with previously diagnosed depression were started with the anti-depression therapy. No patient was offered pulmonary rehabilitation due to lack of availability of a rehabilitation programme at the time of the study.</p>
<fig id="fig2-1479972313493098" position="float">
<label>Figure 2.</label>
<caption>
<p>Gender-specific frequency of depression scores.</p>
</caption>
<graphic xlink:href="10.1177_1479972313493098-fig2.tif"/>
</fig>
</sec>
</sec>
<sec id="section10-1479972313493098">
<title>Discussion</title>
<p>There is a paucity of literature with respect to the prevalence of depression in pulmonary fibrosis. In contrast, several studies have attempted to demonstrate the incidence of depression in COPD patients, with rates varying from 6 to 50% in various reported series.<sup>
<xref ref-type="bibr" rid="bibr28-1479972313493098">28</xref>,<xref ref-type="bibr" rid="bibr31-1479972313493098">31</xref>,<xref ref-type="bibr" rid="bibr32-1479972313493098">32</xref>
</sup> We have shown in a large prospective study that 49.2% of individuals with IPF scored ≥15 on the WDI, suggesting a high frequency and intensity of depressive symptoms in these patients. This is higher than trends seen in the general UK population (i.e. a 2.6% national point prevalence of depression, 11.4% of ‘mixed depression and anxiety’ and a 6% annual and 15% lifetime incidence of an episode of depression)<sup>
<xref ref-type="bibr" rid="bibr33-1479972313493098">33</xref>,<xref ref-type="bibr" rid="bibr34-1479972313493098">34</xref>
</sup> but similar to the levels reported with COPD. In keeping with the literature,<sup>
<xref ref-type="bibr" rid="bibr17-1479972313493098">17</xref>
<xref ref-type="bibr" rid="bibr18-1479972313493098"/>–<xref ref-type="bibr" rid="bibr19-1479972313493098">19</xref>
</sup> female participants were more depressed than their male counterparts, though this was not statistically significant. Further work to elucidate the significance of social support and home circumstances as depressive correlates is needed. Statistically significant negative correlations were found between depression scores and gas transfer factor measurements, FEV<sub>1</sub> and FVC. However, the weakness of the correlations (<italic>r </italic>= −0.20, −0.20 and −0.23, respectively) and the lack of statistically significant correlation with the gas constant and FEV<sub>1</sub>–FVC ratio suggest these are unlikely to be of a significantly pertinent nature. There was also no significant correlation between depression score and duration since diagnosis, age and number of co-morbidities.</p>
<p>Though this questionnaire cannot be used to diagnose depression, it is a valuable screening tool and an effective correlate for depressive symptoms.<sup>
<xref ref-type="bibr" rid="bibr27-1479972313493098">27</xref>,<xref ref-type="bibr" rid="bibr30-1479972313493098">30</xref>
</sup> There is a possibility that some patients scoring high on the questionnaire may have other physical or psychological illness. Conversely, scores &lt;15 may still warrant psychiatric consultation if the stress or dysfunction is substantial.</p>
<p>Many IPF patients faced with a gradual and progressive realisation of the severity and poor prognosis of their condition. Worsening lung function means that daily living is severely affected, which has numerous social and psychological implications. There is presently very limited medical treatment for IPF. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) trial recommends a triple therapy consisting of N-acetyl cysteine, azathioprine and prednisolone,<sup>
<xref ref-type="bibr" rid="bibr36-1479972313493098">36</xref>
</sup> though initial findings from the ongoing phase III Prednisone, Azathioprine, and N-acetylcysteine: A Study That Evaluates Response in IPF (PANTHER-IPF) study suggests increased mortality, poor compliance and lack of therapeutic benefit.<sup>
<xref ref-type="bibr" rid="bibr37-1479972313493098">37</xref>
</sup> The European Respiratory Society further recommends lung transplantation;<sup>
<xref ref-type="bibr" rid="bibr35-1479972313493098">35</xref>
</sup> this appears to be the sole therapeutic treatment at present. 5-year survival rates following lung transplantation have been shown to be as high as 72%.<sup>
<xref ref-type="bibr" rid="bibr38-1479972313493098">38</xref>
</sup> Presently, however, most patients undergoing lung transplantation have other forms of fibrotic lung diseases and eligibility and timing of transplantation that vary from centre to centre.<sup>
<xref ref-type="bibr" rid="bibr35-1479972313493098">35</xref>
</sup> The waiting time for lung transplantation coupled with a median survival of 2–3 years for these patients makes this a difficult option to utilise for many patients. It appears, therefore, that for the present, the World Health Organization’s advice to initiate best supportive care (BSC) remains the most effective strategy to alleviate symptoms and QoL indicators.<sup>
<xref ref-type="bibr" rid="bibr39-1479972313493098">39</xref>
</sup> For IPF patients, BSC must take into account a number of aspects.<list list-type="order">
<list-item>
<p>Appropriate analgesia and O<sub>2</sub> supplementation;</p>
</list-item>
<list-item>
<p>oral opiates to control cough and dyspnoea and control of GORD symptoms, if present;</p>
</list-item>
<list-item>
<p>pulmonary rehabilitation;</p>
</list-item>
<list-item>
<p>cessation of smoking;</p>
</list-item>
<list-item>
<p>optimisation of drug therapy;</p>
</list-item>
<list-item>
<p>physical, psychosocial and spiritual care.</p>
</list-item>
</list>
</p>
<p>There is currently little evaluation of the efficacy of the various aspects of BSC for IPF patients. However, the value of pulmonary rehabilitation in managing COPD is well documented.<sup>
<xref ref-type="bibr" rid="bibr25-1479972313493098">25</xref>
</sup> Deconditioning, severe breathlessness, impaired QoL, nutritional deficit, fatigue and social isolation are common both in patients with COPD and IPF and hence pulmonary rehabilitation may be beneficial in IPF also. Nevertheless, there is a lack of large, well-controlled trials investigating the benefits of pulmonary rehabilitation in this subpopulation. A few observational studies have demonstrated improvement in exercise tolerance and QoL measures over several weeks of pulmonary rehabilitation in IPF patients.<sup>
<xref ref-type="bibr" rid="bibr40-1479972313493098">40</xref>
<xref ref-type="bibr" rid="bibr41-1479972313493098"/>–<xref ref-type="bibr" rid="bibr42-1479972313493098">42</xref>
</sup> Although the severity, disablement and shortened life expectancy of IPF patients might be comparable with other serious illnesses such as cancer and COPD, the disease has met with limited focus, and few rehabilitation programmes have been prepared for patients suffering from IPF. A larger study is needed in order to define the benefits of IPF-specific pulmonary rehabilitation. It is recommended that for now, pulmonary rehabilitation be carried out based on the same criteria as COPD.</p>
<p>The high burden of depression in IPF should not be ignored; in our study, nearly half the patients had high WDI scores. Patients on antidepressants still had high scores for depression suggesting a role for other therapeutic interventions such as cognitive behavioural therapy. Depression should be actively screened in patients with pulmonary fibrosis and appropriate supportive treatment, including antidepressant medication and psychological counselling, be therefore offered.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-1479972313493098">
<label>Conflict of Interest</label>
<p>The authors declared no conflicts of interest.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-1479972313493098">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1479972313493098">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>King</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Pardo</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy</article-title>. <source>Ann Intern Med</source> <year>2001</year>; <volume>134</volume>(<issue>2</issue>): <fpage>136</fpage>–<lpage>151</lpage>.</citation>
</ref>
<ref id="bibr2-1479972313493098">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Collard</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>King</surname>
<given-names>TE</given-names>
<suffix>Jr</suffix>
</name>
</person-group>. <article-title>Classification and natural history of the idiopathic interstitial pneumonias</article-title>. <source>Proc Am Thorac Soc</source> <year>2006</year>; <volume>3</volume>(<issue>4</issue>): <fpage>285</fpage>–<lpage>292</lpage>.</citation>
</ref>
<ref id="bibr3-1479972313493098">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J-W</given-names>
</name>
<name>
<surname>Kyung</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>YH</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical characteristics of idiopathic pulmonary fibrosis patients with diabetes mellitus: the national survey in Korea from 2003 to 2007</article-title>. <source>J Korean Med Sci</source> <year>2012</year>; <volume>27</volume>(<issue>7</issue>): <fpage>756</fpage>–<lpage>760</lpage>.</citation>
</ref>
<ref id="bibr4-1479972313493098">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gribbin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hubbard</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis</article-title>. <source>Respir Med</source> <year>2009</year>; <volume>103</volume>(<issue>6</issue>): <fpage>927</fpage>–<lpage>931</lpage>.</citation>
</ref>
<ref id="bibr5-1479972313493098">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pearson</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>RS</given-names>
</name>
</person-group>. <article-title>Diffuse pulmonary fibrosis and hiatus hernia</article-title>. <source>Thorax</source> <year>1971</year>; <volume>26</volume>(<issue>3</issue>): <fpage>300</fpage>–<lpage>305</lpage>.</citation>
</ref>
<ref id="bibr6-1479972313493098">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raghu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Freudenberger</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Curtis</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Spada</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hayes</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis</article-title>. <source>Eur Respir J</source> <year>2006</year>; <volume>27</volume>(<issue>1</issue>): <fpage>136</fpage>–<lpage>142</lpage>.</citation>
</ref>
<ref id="bibr7-1479972313493098">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fahim</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dettmar</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Morice</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Hart</surname>
<given-names>SP</given-names>
</name>
</person-group>. <article-title>Gastroesophageal reflux and idiopathic pulmonary fibrosis: a prospective study</article-title>. <source>Medicina (Kaunas)</source> <year>2011</year>; <volume>47</volume>(<issue>4</issue>): <fpage>200</fpage>–<lpage>205</lpage>.</citation>
</ref>
<ref id="bibr8-1479972313493098">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tobin</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Pope</surname>
<given-names>CE</given-names>
<suffix>2nd</suffix>
</name>
<name>
<surname>Pellegrini</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Emond</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Sillery</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Raghu</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis</article-title>. <source>Am J Respir Crit Care Med</source> <year>1998</year>; <volume>158</volume>(<issue>6</issue>): <fpage>1804</fpage>–<lpage>1808</lpage>.</citation>
</ref>
<ref id="bibr9-1479972313493098">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raghu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>ST-Y</given-names>
</name>
<name>
<surname>Spada</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hayes</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pellegrini</surname>
<given-names>CA</given-names>
</name>
</person-group>. <article-title>Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series</article-title>. <source>Chest</source> <year>2006</year>; <volume>129</volume>(<issue>3</issue>): <fpage>794</fpage>–<lpage>800</lpage>.</citation>
</ref>
<ref id="bibr10-1479972313493098">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collard</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Lanes</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cortney Hayflinger</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rosenberg</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Hunsche</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Burden of illness in idiopathic pulmonary fibrosis</article-title>. <source>J Med Econ</source> <year>2012</year>; <volume>15</volume>: <fpage>829</fpage>–<lpage>835</lpage>.</citation>
</ref>
<ref id="bibr11-1479972313493098">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dodda</surname>
<given-names>VR</given-names>
</name>
<name>
<surname>Salazar-Schicchi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Spiro</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Combined pulmonary fibrosis and emphysema</article-title>. <source>Respir Care</source> <year>2012</year>; <volume>57</volume>(<issue>3</issue>): <fpage>467</fpage>–<lpage>470</lpage>.</citation>
</ref>
<ref id="bibr12-1479972313493098">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sprunger</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Huie</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Fernandez-Perez</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Solomon</surname>
<given-names>JJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease</article-title>. <source>Eur Respir J</source> <year>2012</year>; <volume>39</volume>(<issue>1</issue>): <fpage>125</fpage>–<lpage>132</lpage>.</citation>
</ref>
<ref id="bibr13-1479972313493098">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klerman</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Weissman</surname>
<given-names>MM</given-names>
</name>
</person-group>. <article-title>Increasing rates of depression</article-title>. <source>JAMA</source> <year>1989</year>; <volume>261</volume>(<issue>15</issue>): <fpage>2229</fpage>–<lpage>2235</lpage>.</citation>
</ref>
<ref id="bibr14-1479972313493098">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joyce</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Oakley-Browne</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Wells</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Bushnell</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Hornblow</surname>
<given-names>AR</given-names>
</name>
</person-group>. <article-title>Birth cohort trends in major depression: increasing rates and earlier onset in New Zealand</article-title>. <source>J Affect Disord</source> <year>1990</year>; <volume>18</volume>(<issue>2</issue>): <fpage>83</fpage>–<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr15-1479972313493098">
<label>15</label>
<citation citation-type="journal">
<collab collab-type="author">Cross-National Collaborative Group</collab>. <article-title>The changing rate of major depression. Cross-national comparisons</article-title>. <source>JAMA</source> <year>1992</year>; <volume>268</volume>(<issue>21</issue>): <fpage>3098</fpage>–<lpage>3105</lpage>.</citation>
</ref>
<ref id="bibr16-1479972313493098">
<label>16</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Murray</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>A</given-names>
</name>
</person-group>. <source>The global burden of disease. A comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020</source>. <publisher-loc>Cambridge, UK</publisher-loc>: <publisher-name>Harvard University Press</publisher-name>, <year>1996</year>.</citation>
</ref>
<ref id="bibr17-1479972313493098">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bland</surname>
<given-names>RC</given-names>
</name>
</person-group>. <article-title>Epidemiology of affective disorders: a review</article-title>. <source>Can J Psychiatry</source> <year>1997</year>; <volume>42</volume>(<issue>4</issue>): <fpage>367</fpage>–<lpage>377</lpage>.</citation>
</ref>
<ref id="bibr18-1479972313493098">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohayon</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Priest</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Guilleminault</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Caulet</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>The prevalence of depressive disorders in the United Kingdom</article-title>. <source>Biol Psychiatry</source> <year>1999</year>; <volume>45</volume>(<issue>3</issue>): <fpage>300</fpage>–<lpage>307</lpage>.</citation>
</ref>
<ref id="bibr19-1479972313493098">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Macera</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Croft</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Giles</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>WK</given-names>
</name>
</person-group>. <article-title>Major depression and all-cause mortality among white adults in the United States</article-title>. <source>Ann Epidemiol</source> <year>1997</year>; <volume>7</volume>(<issue>3</issue>): <fpage>213</fpage>–<lpage>218</lpage>.</citation>
</ref>
<ref id="bibr20-1479972313493098">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zalai</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Szeifert</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Novak</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Psychological distress and depression in patients with chronic kidney disease</article-title>. <source>Semin Dial</source> <year>2012</year>; <volume>25</volume>(<issue>4</issue>): <fpage>428</fpage>–<lpage>438</lpage>.</citation>
</ref>
<ref id="bibr21-1479972313493098">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moussavi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chatterji</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Verdes</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tandon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ustun</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Depression, chronic diseases, and decrements in health: results from the world health surveys</article-title>. <source>Lancet</source> <year>2007</year>; <volume>370</volume>(<issue>9590</issue>): <fpage>851</fpage>–<lpage>858</lpage>.</citation>
</ref>
<ref id="bibr22-1479972313493098">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Vries</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kessels</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Drent</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Quality of life of idiopathic pulmonary fibrosis patients</article-title>. <source>Eur Respir J</source> <year>2001</year>; <volume>17</volume>(<issue>5</issue>): <fpage>954</fpage>–<lpage>961</lpage>.</citation>
</ref>
<ref id="bibr23-1479972313493098">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elfferich</surname>
<given-names>MDP</given-names>
</name>
<name>
<surname>De Vries</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Drent</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Type D or “distressed” personality in sarcoidosis and idiopathic pulmonary fibrosis</article-title>. <source>Sarcoidosis Vasc Diffuse Lung Dis</source> <year>2011</year>; <volume>28</volume>(<issue>1</issue>): <fpage>65</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr24-1479972313493098">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Navaratnam</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Fleming</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>West</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>CJP</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Fogarty</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>The rising incidence of idiopathic pulmonary fibrosis in the U.K</article-title>. <source>Thorax</source> <year>2011</year>; <volume>66</volume>(<issue>6</issue>): <fpage>462</fpage>–<lpage>467</lpage>.</citation>
</ref>
<ref id="bibr25-1479972313493098">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harrison</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Greening</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>JEA</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>MDL</given-names>
</name>
<name>
<surname>Steiner</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>SJ</given-names>
</name>
</person-group>. <article-title>Have we underestimated the efficacy of pulmonary rehabilitation in improving mood?</article-title> <source>Respir Med</source> <year>2012</year>; <volume>106</volume>(<issue>6</issue>): <fpage>838</fpage>–<lpage>844</lpage>.</citation>
</ref>
<ref id="bibr26-1479972313493098">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ries</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Bauldoff</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Carlin</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Casaburi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Emery</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Mahler</surname>
<given-names>DA</given-names>
</name>
<etal/>
</person-group>. <article-title>Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines</article-title>. <source>Chest</source> <year>2007</year>; <volume>131</volume>(<issue>5 Suppl</issue>): <fpage>4S</fpage>–<lpage>42S</lpage>.</citation>
</ref>
<ref id="bibr27-1479972313493098">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snaith</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>M.</given-names>
</name>
</person-group> <article-title>Assessment of the severity of primary depressive illness. Wakefield Self-assessment Depression Inventory</article-title>. <source>Psychol Med</source> <year>1971</year>; <volume>1</volume>(<issue>2</issue>): <fpage>143</fpage>–<lpage>149</lpage>.</citation>
</ref>
<ref id="bibr28-1479972313493098">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Manen</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Bindels</surname>
<given-names>PJE</given-names>
</name>
<name>
<surname>Dekker</surname>
<given-names>FW</given-names>
</name>
<name>
<surname>IJzermans</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Van der Zee</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Schadé</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Risk of depression in patients with chronic obstructive pulmonary disease and its determinants</article-title>. <source>Thorax</source> <year>2002</year>; <volume>57</volume>(<issue>5</issue>): <fpage>412</fpage>–<lpage>416</lpage>.</citation>
</ref>
<ref id="bibr29-1479972313493098">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sutcliffe</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Lincoln</surname>
<given-names>NB</given-names>
</name>
</person-group>. <article-title>The assessment of depression in aphasic stroke patients: the development of the stroke aphasic depression questionnaire</article-title>. <source>Clin Rehabil</source> <year>1998</year>; <volume>12</volume>(<issue>6</issue>): <fpage>506</fpage>–<lpage>513</lpage>.</citation>
</ref>
<ref id="bibr30-1479972313493098">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lincoln</surname>
<given-names>NB</given-names>
</name>
<name>
<surname>Nicholl</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Flannaghan</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Van der Gucht</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>The validity of questionnaire measures for assessing depression after stroke</article-title>. <source>Clin Rehabil</source> <year>2003</year>; <volume>17</volume>(<issue>8</issue>): <fpage>840</fpage>–<lpage>846</lpage>.</citation>
</ref>
<ref id="bibr31-1479972313493098">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Light</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Merrill</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Despars</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Mutalipassi</surname>
<given-names>LR</given-names>
</name>
</person-group>. <article-title>Prevalence of depression and anxiety in patients with COPD. Relationship to functional capacity</article-title>. <source>Chest</source> <year>1985</year>; <volume>87</volume>(<issue>1</issue>): <fpage>35</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr32-1479972313493098">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneider</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jick</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Bothner</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Meier</surname>
<given-names>CR</given-names>
</name>
</person-group>. <article-title>COPD and the risk of depression</article-title>. <source>Chest</source> <year>2010</year>; <volume>137</volume>(<issue>2</issue>): <fpage>341</fpage>–<lpage>347</lpage>.</citation>
</ref>
<ref id="bibr33-1479972313493098">
<label>33</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Singleton</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bumpstead</surname>
<given-names>R</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Meltzer</surname>
<given-names>H.</given-names>
</name>
</person-group> <source>Psychiatric morbidity among adults living in private households, 2000</source>. <publisher-name>Office for National Statistics</publisher-name>.</citation>
</ref>
<ref id="bibr34-1479972313493098">
<label>34</label>
<citation citation-type="book">
<collab collab-type="author">National Collaborating Centre for Mental Health</collab>. <source>Depression in adults (update): full NICE guideline</source>. <publisher-name>National Institute for Health and Clinical Excellence</publisher-name>, <year>2009</year>.</citation>
</ref>
<ref id="bibr35-1479972313493098">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raghu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Collard</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Egan</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Behr</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>KK</given-names>
</name>
<etal/>
</person-group>. <article-title>An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management</article-title>. <source>Am J Respir Crit Care Med</source> <year>2011</year>; <volume>183</volume>(<issue>6</issue>): <fpage>788</fpage>–<lpage>824</lpage>.</citation>
</ref>
<ref id="bibr36-1479972313493098">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Demedts</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Behr</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Buhl</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Costabel</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Dekhuijzen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jansen</surname>
<given-names>HM</given-names>
</name>
<etal/>
</person-group>. <article-title>High-dose acetylcysteine in idiopathic pulmonary fibrosis</article-title>. <source>N Engl J Med</source> <year>2005</year>; <volume>353</volume>(<issue>21</issue>): <fpage>2229</fpage>–<lpage>2242</lpage>.</citation>
</ref>
<ref id="bibr37-1479972313493098">
<label>37</label>
<citation citation-type="web">
<collab collab-type="author">National Heart, Lung and Blood Institute</collab>. <article-title>PANTHER-IPF study</article-title>. <comment>NIH</comment>, <ext-link ext-link-type="uri" xlink:href="http://www.nhlbi.nih.gov/new/pantherQA.htm">http://www.nhlbi.nih.gov/new/pantherQA.htm</ext-link> <comment>(accesed 25 July 2012)</comment>.</citation>
</ref>
<ref id="bibr38-1479972313493098">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keating</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Levvey</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kotsimbos</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Whitford</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Westall</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years</article-title>. <source>Transplant Proc</source> <year>2009</year>; <volume>41</volume>(<issue>1</issue>): <fpage>289</fpage>–<lpage>291</lpage>.</citation>
</ref>
<ref id="bibr39-1479972313493098">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bradley</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Branley</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Egan</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Greaves</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Hansell</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>NK</given-names>
</name>
<etal/>
</person-group>. <article-title>Interstitial lung disease guideline: the British thoracic society in collaboration with the thoracic society of Australia and New Zealand and the Irish thoracic society</article-title>. <source>Thorax</source> <year>2008</year>; <volume>63</volume>(<issue>Suppl 5</issue>): <fpage>v1</fpage>–<lpage>v58</lpage>.</citation>
</ref>
<ref id="bibr40-1479972313493098">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naji</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Connor</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Donnelly</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>McDonnell</surname>
<given-names>TJ</given-names>
</name>
</person-group>. <article-title>Effectiveness of pulmonary rehabilitation in restrictive lung disease</article-title>. <source>J Cardiopulm Rehabil</source> <year>2006</year>; <volume>26</volume>(<issue>4</issue>): <fpage>237</fpage>–<lpage>243</lpage>.</citation>
</ref>
<ref id="bibr41-1479972313493098">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jastrzebski</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gumola</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gawlik</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kozielski</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Dyspnea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation</article-title>. <source>J Physiol Pharmacol</source> <year>2006</year>; <volume>57</volume>(<issue>Suppl 4</issue>): <fpage>139</fpage>–<lpage>148</lpage>.</citation>
</ref>
<ref id="bibr42-1479972313493098">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salhi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Troosters</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Behaegel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Joos</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Derom</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Effects of pulmonary rehabilitation in patients with restrictive lung diseases</article-title>. <source>Chest</source> <year>2010</year>; <volume>137</volume>(<issue>2</issue>): <fpage>273</fpage>–<lpage>279</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>